Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of lumicitabine in infants and children after RSV infection
jRCT2080223732Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial in respiratory syncytial virus disease (RSV) and asthma comparing Prior lumicitabine arm with Prior placebo arm (2 arms). Primary endpoints: Incidence of clinically diagnosed asthma, Frequency of wheezing and 1 more. Started Nov 2017; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)asthma
Beyond the preview
Go deeper on jRCT2080223732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223732.